Every material Form 8-K Bausch Health Companies Inc. has filed with the SEC since July 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bausch Health reported third-quarter 2026 revenue of $2.94 billion, up 10% from the prior year, and GAAP diluted EPS of $1.15 versus $0.48. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance and authorized a $50 million share repurchase program. The results and higher guidance point to improved profitability for shareholders, though the company's guidance notes ongoing tariff uncertainty.
Q3 2026 consolidated revenue was $2.94 billion, up 10% (8% organic), versus $2.68 billion in Q3 2025
GAAP diluted EPS was $1.15 versus $0.48; adjusted diluted EPS was $1.77 versus $1.16, an increase of 53%
Full-year 2026 consolidated revenue guidance is $10.975 billion to $11.175 billion, and Adjusted EBITDA guidance is $4.315 billion to $4.415 billion
Board authorized a $50 million share repurchase program, primarily to offset dilution from management equity awards expected to vest in 2027
Bausch Health reported second-quarter 2026 revenue of $2.85 billion, up 13% from a year earlier, with GAAP diluted earnings per share of $0.68 versus $0.40 and adjusted diluted earnings per share of $1.26 versus $0.90. The company raised its full-year 2026 revenue, Adjusted EBITDA and Adjusted Cash Flows from Operations guidance for Bausch Health excluding Bausch + Lomb, which points to stronger results for shareholders.
Q2 2026 consolidated revenue was $2.85 billion, up 13% on a reported basis and 11% organic, versus $2.53 billion a year earlier
GAAP net income attributable to Bausch Health was $258 million, compared with $148 million in Q2 2025
Consolidated Adjusted EBITDA was $1,075 million, up from $842 million, and operating income was $740 million, up from $444 million
Full-year 2026 Bausch Health (excluding Bausch + Lomb) revenue guidance is $10.790 billion to $11.040 billion, with Adjusted EBITDA guidance of $4.050 billion to $4.175 billion
Michael Goettler resigned from the Bausch Health Board of Directors, effective June 30, 2026, to take up the role of President and Chief Executive Officer of Knoa Pharma LLC. The company said his resignation did not result from any disagreement over its operations, policies or practices. The filing contains no financial figures, and the change affects board composition only.
Goettler notified the company of his resignation on June 26, 2026; it takes effect June 30, 2026.
He is joining Knoa Pharma LLC as President and Chief Executive Officer.
The company states the resignation was not due to any disagreement on its operations, policies or practices.
Board Chairperson John A. Paulson thanked Goettler for his service in the July 1, 2026 press release.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bausch Health Companies Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →